Coronavirus Update

FDA Authorizes First Covid-19 and Flu Combination Test for Use with Home-Collected Samples

The U.S. Food and Drug Administration authorized the first diagnostic test for at home collection of patient samples to detect both Covid-19 and influenza A and B (flu).

The FDA authorized Quest Diagnostics RC Covid-19 +Flu RT-PCR Test for prescription use with the Quest Diagnostics Self-Collection Kit for Covid-19 +Flu by individuals who are suspected of respiratory viral infection consistent with Covid-19 when home collection is determined to be appropriate by an individual’s healthcare provider. Under a health care provider’s order, patients can collect a sample at home and ship it to a Quest Diagnostics laboratory for analysis following the instructions included with the self-collection kit.

More details on the FDA website.

06.12.2020

Related articles

Photo

News • Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Blood test for ME/CFS unveiled

Chronic fatigue (ME/CFS) affects millions worldwide, but is poorly understood and has long lacked reliable diagnostic tools. Now, a new blood test claims to diagnose the condition with 96% accuracy.

Photo

News • Tracking current and emerging threats

Combined wastewater and individual testing for better virus detection

When someone is infected with a virus, traces of it are shed in their bodily waste and end up in the sewage system. Thus, combined wastewater and individual testing can benefit public health response.

Photo

News • Environmental impact

Plastic waste from test kits: call for urgent action

During the Covid-19 pandemic, everyone became familiar with lateral flow tests. These tests generate a lot of plastic waste, creating an environmental crisis. Experts call for urgent action.

Related products

Subscribe to Newsletter